14-3-3ζ regulates immune response through stat3 signaling in oral squamous cell carcinoma

Molecules and Cells

Volumn 38, Issue 2, 2015, Pages 112-121

  Han, Xinguang ^a   Han, Yongfu ^a   Jiao, Huifeng ^a   Jie, Yaqiong ^b  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

^b ZHENGZHOU UNIVERSITY   (China)

Author keywords

14 3 3 ; Immune response; Oral squamous cell carcinoma; Stat3; Tumor inflammation

Indexed keywords

GAMMA INTERFERON; LIPOPOLYSACCHARIDE; STAT3 PROTEIN; STRATIFIN;

ANTIGEN RECOGNITION; ARTICLE; CANCER TISSUE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; FIBROBLAST; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE EVASION; IMMUNOREGULATION; KERATINOCYTE; MOUTH SQUAMOUS CELL CARCINOMA; PERITONEUM MACROPHAGE; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; SUPERNATANT; T LYMPHOCYTE; UPREGULATION;

EID: 84947076511     PISSN: 10168478     EISSN: 02191032     Source Type: Journal    
DOI: 10.14348/molcells.2015.02101     Document Type: Article

References (43)

1. Aitken, A. (1996). 14-3-3 and its possible role in co-ordinating multiple signalling pathways. Trends Cell Biol. 6, 341-347.
2. Bettendorf, O., Piffko, J., and Bankfalvi, A. (2004). Prognostic and predictive factors in oral squamous cell cancer: important tools for planning individual therapy? Oral Oncol. 40, 110-119.
3. Bromberg, J.F., Wrzeszczynska, M.H., Devgan, G., Zhao, Y., Pestell, R.G., Albanese, C., and Darnell, J.E., Jr. (1999). Stat3 as an oncogene. Cell 98, 295-303.
4. Butt, A.Q., Ahmed, S., Maratha, A., and Miggin, S.M. (2012). 14-3- 3epsilon and 14-3-3sigma inhibit Toll-like receptor (TLR)-mediated proinflammatory cytokine induction. J. Biol. Chem. 287, 38665- 38679.
5. Choi, J.E., Hur, W., Jung, C.K., Piao, L.S., Lyoo, K., Hong, S.W., Kim, S.W., Yoon, H.Y., and Yoon, S.K. (2011). Silencing of 14 3-3zeta over-expression in hepatocellular carcinoma inhibits tumor growth and enhances chemosensitivity to cis-diammined dichloridoplatium. Cancer Lett. 303, 99-107.
6. Danes, C.G., Wyszomierski, S.L., Lu, J., Neal, C.L., Yang, W, and Yu, D. (2008). 14-3-3 zeta down-regulates p53 in mammary epithelial cells and confers luminal filling. Cancer Res. 68, 1760-1767.
7. Dhillon, A.S., Yip, Y.Y., Grindlay, G.J., Pakay, J.L., Dangers, M., Hillmann, M., Clark, W., Pitt, A., Mischak, H., and Kolch, W. (2009). The C-terminus of Raf-1 acts as a 14-3-3-dependent activation switch. Cell. Signal. 21, 1645-1651.
8. Faisal, A., Saurin, A., Gregory, B., Foxwell, B., and Parker, P.J. (2008). The scaffold MyD88 acts to couple protein kinase Cepsilon to Toll-like receptors. J. Biol. Chem. 283, 18591-18600.
9. Fanger, G.R., Widmann, C., Porter, A.C., Sather, S., Johnson, G.L., and Vaillancourt, R.R. (1998). 14-3-3 proteins interact with specific MEK kinases. J. Biol. Chem. 273, 3476-3483.
10. Hashiguchi, M., Sobue, K., and Paudel, H.K. (2000). 14-3-3zeta is an effector of tau protein phosphorylation. J. Biol. Chem. 275, 25247-25254.
11. He, T.C., Zhou, S., da Costa, L.T., Yu, J., Kinzler, K.W., and Vogelstein, B. (1998). A simplified system for generating recombinant adenoviruses. Proc. Natl. Acad. Sci. USA 95, 2509-2514.
12. Ichimura, T., Isobe, T., Okuyama, T., Takahashi, N., Araki, K., Kuwano, R., and Takahashi, Y. (1988). Molecular cloning of cDNA coding for brain-specific 14-3-3 protein, a protein kinase- dependent activator of tyrosine and tryptophan hydroxylases. Proc. Natl. Acad. Sci. USA 85, 7084-7088.
13. Jang, J.S., Cho, H.Y., Lee, Y.J., Ha, W.S., and Kim, H.W. (2004). The differential proteome profile of stomach cancer: identification of the biomarker candidates. Oncol. Res. 14, 491-499.
14. Jemal, A., Bray, F., Center, M.M., Ferlay, J., Ward, E., and Forman, D. (2011). Global cancer statistics. CA Cancer J. Clin. 61, 69-90.
15. Kwak, B., Mulhaupt, F., Myit, S., and Mach, F. (2000). Statins as é newly recognized type of immunomodulator. Nat Med. 6, 1399-1402.
16. Lakshmi Narendra, B., Eshvendar Reddy, K., Shantikumar, S., and Ramakrishna, S. (2013). Immune system: a double-edged sword in cancer. Inflamm. Res. 62, 823-834.
17. Leeman, R.J., Lui, V.W., and Grandis, J.R. (2006). STAT3 as a therapeutic target in head and neck cancer. Expert Opin. Biol. Ther. 6, 231-241.
18. Levy, D.E., and Darnell, J.E., Jr. (2002). Stats: transcriptional control and biological impact. Nat. Rev. Mol. Cell Biol. 3, 651-662.
19. Li, Z., Zhao, J., Du, Y., Park, H.R., Sun, S.Y., Bernal-Mizrachi, L., Aitken, A., Khuri, F.R., and Fu, H. (2008). Down-regulation of 14-3-3zeta suppresses anchorage-independent growth of lung cancer cells through anoikis activation. Proc. Natl. Acad. Sci. USA 105, 162-167.
20. Lin, M., Morrison, C.D., Jones, S., Mohamed, N., Bacher, J., and Plass, C. (2009). Copy number gain and oncogenic activity of YWHAZ/14-3-3zeta in head and neck squamous cell carcinoma. Int. J. Cancer 125, 603-611.
21. Matta, A., Bahadur, S., Duggal, R., Gupta, S.D., and Ralhan, R. (2007). Over-expression of 14-3-3zeta is an early event in oral cancer. BMC Cancer 7, 169.
22. Min, B.M., Lee, G., Kim, S.H., Nam, Y.S., Lee, T.S., and Park, W.H. (2004). Electrospinning of silk fibroin nanofibers and its effect on the adhesion and spreading of normal human keratinocytes and fibroblasts in vitro. Biomaterials 25, 1289-1297.
23. Neal, C.L., and Yu, D. (2010). 14-3-3zeta as a prognostic marker and therapeutic target for cancer. Expert Opin. Ther. Targets 14, 1343-1354.
24. Neal, C.L., Yao, J., Yang, W., Zhou, X., Nguyen, N.T., Lu, J., Danes, C.G., Guo, H., Lan, K.H., Ensor, J, et al. (2009). 14-3-3zeta overexpression defines high risk for breast cancer recurrence and promotes cancer cell survival. Cancer Res. 69, 3425-3432.
25. Neal, C.L., Xu, J., Li, P., Mori, S., Yang, J., Neal, N.N., Zhou, X., Wyszomierski, S.L., and Yu, D. (2012). Overexpression of 14-3- 3zeta in cancer cells activates PI3K via binding the p85 regulatory subunit. Oncogene 31, 897-906.
26. O’Shea, J.J., Holland, S.M., and Staudt, L.M. (2013). JAKs and STATs in immunity, immunodeficiency, and cancer. N. Engl. J. Med. 368, 161-170.
27. Ochsenbein, A.F., Sierro, S., Odermatt, B., Pericin, M., Karrer, U., Hermans, J., Hemmi, S., Hengartner, H., and Zinkernagel, R.M. (2001). Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. Nature 411, 1058-1064.
28. Parkin, D.M., Pisani, P., and Ferlay, J. (1999). Estimates of the worldwide incidence of 25 major cancers in 1990. Int. J. Cancer 80, 827-841.
29. Reuther, G.W., and Pendergast, A.M. (1996). The roles of 14-3-3 proteins in signal transduction. Vitam. Horm. 52, 149-175.
30. Saurin, A.T., Durgan, J., Cameron, A.J., Faisal, A., Marber, M.S., and Parker, P.J. (2008). The regulated assembly of a PKCepsilon complex controls the completion of cytokinesis. Nat. Cell Biol. 10, 891-901.
31. Schuster, T.B., Costina, V., Findeisen, P., Neumaier, M., and Ahmad- Nejad, P. (2011). Identification and functional characterization of 14-3-3 in TLR2 signaling. J. Proteome Res. 10, 4661-4670.
32. Silver, D.L., Naora, H., Liu, J., Cheng, W., and Montell, D.J. (2004). Activated signal transducer and activator of transcription (STAT) 3: localization in focal adhesions and function in ovarian cancer cell motility. Cancer Res. 64, 3550-3558.
33. Sriuranpong, V., Park, J.I., Amornphimoltham, P., Patel, V., Nelkin, B.D., and Gutkind, J.S. (2003). Epidermal growth factor receptor-independent constitutive activation of STAT3 in head and neck squamous cell carcinoma is mediated by the autocrine/paracrine stimulation of the interleukin 6/gp130 cytokine system. Cancer Res. 63, 2948-2956.
34. Sun, L., Stoecklin, G., Van Way, S., Hinkovska-Galcheva, V., Guo, R.F., Anderson, P., and Shanley, T.P. (2007). Tristetraprolin (TTP)-14-3-3 complex formation protects TTP from depho- sphorylation by protein phosphatase 2a and stabilizes tumor necrosis factor-alpha mRNA. J. Biol. Chem. 282, 3766-3777.
35. Wang, T., Niu, G., Kortylewski, M., Burdelya, L., Shain, K., Zhang, S., Bhattacharya, R., Gabrilovich, D., Heller, R., Coppola, D., et al. (2004). Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat. Med. 10, 48-54.
36. Wang, M.L., Shin, M.E., Knight, P.A., Artis, D., Silberg, D.G., Suh, E., and Wu, G.D. (2005). Regulation of RELM/FIZZ isoform expression by Cdx2 in response to innate and adaptive immune stimulation in the intestine. Am. J. Physiol. Gastrointest Liver Physiol. 288, G1074-1083.
37. Wang, B., Liu, K., Lin, H.Y., Bellam, N., Ling, S., and Lin, W.C. (2010). 14-3-3Tau regulates ubiquitin-independent proteasomal degradation of p21, a novel mechanism of p21 downregulation in breast cancer. Mol. Cell. Biol. 30, 1508-1527.
38. Wang, X., Crowe, P.J., Goldstein, D., and Yang, J.L. (2012). STAT3 inhibition, a novel approach to enhancing targeted therapy in human cancers (review). Int. J. Oncol. 41, 1181-1191.
39. Wei, D., Le, X., Zheng, L., Wang, L., Frey, J.A., Gao, A.C., Peng, Z., Huang, S., Xiong, H.Q., Abbruzzese, J.L., et al. (2003). Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis. Oncogene 22, 319-329.
40. Yaffe, M.B., Rittinger, K., Volinia, S., Caron, P.R., Aitken, A., Leffers, H., Gamblin, S.J., Smerdon, S.J., and Cantley, L.C. (1997). The structural basis for 14-3-3:phosphopeptide binding specificity. Cell 91, 961-971.
41. Yang, X., Cao, W., Zhang, L., Zhang, W., Zhang, X., and Lin, H. (2012). Targeting 14-3-3zeta in cancer therapy. Cancer Gene Ther. 19, 153-159.
42. Yu, H., Kortylewski, M., and Pardoll, D. (2007). Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat. Rev. Immunol. 7, 41-51.
43. Zhang, J, Chen, F, Li, W, Xiong, Q, Yang, M, Zheng, P, Li, C, Pei, J, and Ge, F. (2012). 14-3-3zeta interacts with stat3 and regulates its constitutive activation in multiple myeloma cells. PLoS One 7, e29554.